Electrochemical Immunosensor for the Quantification of Galectin-3 in Saliva.

Autor: Pittman TW; Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, USA., Zhang X; Griffith Institute for Drug Discover, Griffith University, Nathan, Australia., Punyadeera C; Griffith Institute for Drug Discover, Griffith University, Nathan, Australia.; Menzies Health Institute, Griffith University, Gold Coast, Australia.; Translational Research Institute, Woolloongabba, Australia., Henry CS; Department of Chemistry, Colorado State University, Fort Collins, Colorado 80523, USA.; Metallurgy and Materials Science Research Institute, Chulalongkorn University, Soi Chula 12, Phayathai Rd., Pathumwan, Bangkok 10330, Thailand.
Jazyk: angličtina
Zdroj: Sensors and actuators. B, Chemical [Sens Actuators B Chem] 2024 Feb 01; Vol. 400 (Pt B). Date of Electronic Publication: 2023 Oct 19.
DOI: 10.1016/j.snb.2023.134811
Abstrakt: Heart failure (HF) is an emerging epidemic and remains a major clinical and public health problem. Advances in the healthcare management of HF may lead to lower morbidity and mortality rates but require diagnostics to guide the process. Current diagnostics/prognostics approaches rely on expensive equipment, centralized facilities and trained personnel, marginalizing healthcare access in developing countries and rural communities. These issues have led researchers to focus on developing portable and affordable diagnostics that can be deployed at the point-of-care (POC). Typically, HF biomarkers are measured in blood not saliva. Recently, our team correlated concentrations of salivary Galectin-3 (Gal-3) to outcomes in patients with HF. We have developed an analytical device which consists of an immunoassay based on a screen-printed carbon electrode (SPCE) to quantify Gal-3 levels in saliva samples. Using 10 μL of saliva, the proposed electrochemical immunoassay achieved a concentration dependent signal response in the clinically relevant range with a limit of detection of 9.66 ng/mL. In addition, the storage stability of the modified electrode was investigated, and only a 10.9% loss in current response over a 35-day period. The results of the immunoassay on the modified SPCEs suggest validity as a POC biosensor system for the management of HF.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests.
Databáze: MEDLINE
Externí odkaz: